Skip to main content
Equibles
AMGN logo

AMGN · Amgen Inc

Track AMGN — free

Use AMGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AMGN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$415.21 -2.63 (-0.63%) At close · Aug 14
Market Cap
$224.48B
Shares
540.63M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$415.21 Open$413.76 Day$410.50–416.03 52W close$271.18–417.84 Avg vol 30d2.5M Short int13.3M · 2.5% float · 5.2d Short vol54% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +19%
      above
      Price vs 50-day avg +12%
      above
      RSI (14) 70
      overbought
      MACD trend Positive
      52-week position 98%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +13%
      trailing
      6-month return +9%
      trailing
      YTD return +27%
      this year
      Relative strength −4%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $370 › 200d $349 — 50d above 200d
      Institutional flow Distributing
      -2% holders QoQ · +172 funds added
      Insider flow Distributing
      Net -$4.1M over 90 days · 100% sells
      Short interest Rising
      2.46% of float · ▲ +3.4% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      3,104 holders — near 3-yr high, broad support
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +9%
      Y/Y
      EPS growth +88%
      Y/Y
      Free cash flow $8.1B
      Valuation P/E 25.8
      below peers
      Buyback $6.8B
      remaining
      Balance sheet $45.3B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 27%
      annualized · 1-yr
      Max drawdown −17%
      past year
      ATR 2.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 4, 2026
      Total revenues · full year 2026 $38.2B – $39.4B
      EPS · full year 2026 $15.80 – $17.08
      Tax rate · full year 2026 14.5% – 16%
      EPS · full year 2026 $22.30 – $23.50
      Tax rate · full year 2026 15% – 16.5%
      Capital expenditures · full year 2026 $2.6B
      Share repurchases · full year 2026 at least $3B
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Total revenues · full year 2025 $35.8B – $36.6B
      EPS · full year 2025 $13.76 – $14.60
      Tax rate · full year 2025 14.5% – 16%
      EPS · full year 2025 $20.60 – $21.40
      Tax rate · full year 2025 15% – 16.5%
      Guided vs delivered · last 2 settled
      Total revenues full year 2025
      guided $35.8B – $36.6B
      $36.75B Beat +1.5%
      EPS full year 2025
      guided $13.76 – $14.60
      $14.23 In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +19% Bullish
      Price vs 50-day avg
      +12% Bullish
      RSI (14)
      70 Bearish
      MACD trend
      Positive Bullish
      52-week position
      98% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $370 › 200d $349 — 50d above 200d
      Institutional flow Distributing
      -2% holders QoQ · +172 funds added
      Insider flow Distributing
      Net -$4.1M over 90 days · 100% sells
      Short interest Rising
      2.46% of float · ▲ +3.4% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      3,104 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $271 Now $415 · 98% Range high $418
      vs 200-day avg +19% vs 50-day avg +12%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Debt leverage ratio non-GAAP 3.2 as of December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - General — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AMGN
      Amgen Inc
      this stock
      		$224.48B +26.9% +8.8% 25.8 2.5%
      LLY
      ELI LILLY & Co
      		 $1.11T +9.8% +44.7% 39.6 1.0%
      JNJ
      Johnson & Johnson
      		 $627.42B +25.8% +6.0% 30.2 1.1%
      ABBV
      AbbVie Inc.
      		 $440.83B +9.2% +8.6% 70.5 1.3%
      MRK
      Merck & Co., Inc.
      		 $335.14B +29.1% +1.3% 108.7 1.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      3,104
      % held
      84.2%
      Net QoQ
      +18.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,195
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      13.3M
      Days to cover
      5.2d
      Change
      +435.6K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      8
      Value
      $2.9K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      40.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$4.1M
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      David J. Taylor
      Amount
      $1.0K–$15.0K
      Traded
      Jun 5, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $36.8B
      Net income (FY)
      $7.7B
      EPS diluted
      $14.23
      View
      Buybacks
      Remaining
      $6.8B
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 5, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $516.8K
      Shares
      1.3K
      Filed
      Aug 13, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 6, 2026
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      AMGN +1.0% +13.4% +9.4% +7.8% +26.9%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +0.6% +8.9% -4.3% +3.9% +13.0%

      Capital returns

      Latest dividend
      $2.52 / share · ex May 15, 2026
      Declared · upcoming
      $2.52 / share · ex Aug 21, 2026
      Raised 5.9%
      Paid (TTM)
      $9.80 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.36%
      Buyback program · as of Jun 30, 2026
      Authorized
      —
      Spent (derived)
      —
      Remaining
      $6.80B

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 318154 CUSIP 031162100 13F (30d) 2600 filings 2534 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)